Skip to main content
. 2016 Nov 18;6(1):3–11. doi: 10.1002/cam4.799

Figure 2.

Figure 2

PFS from start of lenalidomide for MDS/AML, NHM and non‐SPM groups. Two‐year progression‐free survival was 50% (95% CI, 11.10–80.37%) in the MDS/AML group, 60% (95% CI, 12.57–88.18%) in the NHM group and 22.28% (95% CI, 16.58–28.53%) in the Non‐SPM group, Log‐rank P = 0.077 Wilcoxon P = 0.016.